Weekly Rundown: Key Catalysts for Small-Cap Stocks (December 29 – January 2)

From recent disclosures to corporate developments, we’ve highlighted the top small-cap catalysts to watch. As we close out 2025 and turn the page to 2026, this week offers a fresh start—bringing new momentum, strategic updates, and a preview of where investor focus may shift in Q1. Here’s your weekly preview (December 29 – January 2).

--

Material Events This Week:

● FTEL > Declared a $0.10 interim dividend payable January 13, 2026, to shareholders of record as of December 30. Additionally, the company launched a one-time Shareholder Loyalty Program offering up to $0.15 per share in staged cash payments for eligible long-term holders who maintain book-entry ownership for 30, 60, and 90 days after the loyalty start date of December 29, 2025.

● SES > Hosting its 5th annual Battery World event on December 29, where it will unveil the upgraded MU-1.5 Molecular Universe platform, announce an on-premise solution for enterprise clients, and outline plans to triple cell production capacity at its Korea plant to meet demand from drone customers. SES will also provide updates on integration of UZ Energy’s hardware with its software.

● GPMT > Declared a quarterly cash dividend of $0.05 per share for Q4, payable January 15, 2026, to holders of record as of December 30, 2025.

● ELOG > Subsidiary Guizhou Tianrun entered a RMB 42.5 million (~$6.04M USD) subcontract to begin construction on a 50 MW photovoltaic power generation project in Hebei. Work is scheduled to begin by December 31, 2025.

● ROLR > Through its Malta subsidiary, entered an agreement to acquire Happy Hour Solutions Ltd., which holds a valid Estonian remote gambling license. The acquisition includes the domain www.casinoroom.com and is expected to close by December 31, 2025.

● TSI > Declared a quarterly distribution of $0.13 per share, comprising $0.065 in regular and $0.065 in special year-end distribution, payable January 9, 2026, to shareholders of record on December 31.

● NAMI > Announced the global limited pre-sale launch of its AI-powered, education-focused smart glasses, developed in partnership with MICROLUMIN. Product set to be released December 31, 2025.

● CHMI > Declared a $0.10 Q4 dividend, payable January 30, 2026, to shareholders of record on December 31.

● DOMH > Revised payment timeline for its previously announced ~$10M ($0.44/share) special dividend. It is now payable on or around January 26, 2026, to shareholders of record as of January 5, 2026.

● TKLF > Subsidiary entered a $1.28M investment agreement to expand directly operated retail stores in Hong Kong and Australia. The investor, who will join TKLF HK's board, will commit funds by December 31, 2025, and oversee strategic operations, marketing, staffing, and leasing.

● OTLK > PDUFA goal date for ONS-5010 set for December 31, 2025.

● XRX > Declared a quarterly dividend of $0.025 per share, payable January 30, 2026, to shareholders of record December 31.

● LOAN > Declared a quarterly dividend of $0.115 per share, payable January 15, 2026, to holders of record December 31.

● BGS > Declared a regular quarterly dividend of $0.19 per share, payable January 26, 2026, to shareholders of record as of December 31.

● BHR > Declared a $0.05 per share Q4 dividend, payable January 15, 2026, to shareholders of record as of December 31.

● CETX > Announced plans to acquire Invocon, Inc., a Texas-based aerospace systems firm with decades of mission-critical flight hardware deployments. Deal valued at $7.06M and expected to close around January 1, 2026.

● REVB > Submitted end-of-Phase 1 meeting package for Gemini to the FDA, targeting treatment of acute kidney injury (AKI). Meeting to occur before year-end; additional results from the PRIME study are expected.

● SONM > Filed preliminary proxy for shareholder vote on its proposed asset sale to NEXA, with a special meeting set for December 30, 2025, at 6:00 a.m. PT. Also exploring a secondary public vehicle transaction.

● SGBX > Annual Meeting of Stockholders scheduled for December 29, 2025, where approval of a key phase in the merger with Olenox and Machfu is on the agenda. The merger would mark a strategic shift to energy and AI infrastructure.

● CTSO > Submitted a De Novo pre-submission package to the FDA for DrugSorb™-ATR. A meeting is expected in Q4 2025 or early Q1 2026.

● NMRA > On track to report data from its Phase 1b study of NMRA-511 in Alzheimer’s agitation around year-end 2025.

● WHWK > Remains on track to submit IND filings for HWK-007 and HWK-016 before year-end 2025.

● CABA > Anticipates FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ by the end of 2025.

● IPSC > Preparing to enter IND-enabling studies for CNTY-813, a beta islet therapy for Type 1 diabetes, by year-end.

● RLYB > Expected to report data from its Phase 1 RLYB116 study in Q4. The program targets immune platelet transfusion refractoriness and APS.

● MODD > Submitted its Pivot patch pump for 510(k) clearance. The company expects FDA questions by year-end and is preparing for a potential 2026 launch.

● DUO > Entered a $34.3M agreement to acquire AI assets. Deal must close by December 29, 2025, or may be terminated. Earnout payments based on future revenue increases.

● SMTK > Extended LOI exclusivity period with Jericho Energy Ventures to February 3, 2026. The company must invest $500K in Jericho shares by December 31 to retain LOI rights.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.